Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: Progression-free survival and overall survival

World Neurosurgery

Volumn 77, Issue 1, 2012, Pages 130-134

  Burkhardt, Jan Karl ^a   Riina, Howard ^a   Shin, Benjamin J ^a   Christos, Paul ^a   Kesavabhotla, Kartik ^a   Hofstetter, Christoph P ^a   Tsiouris, Apostolos John ^a   Boockvar, John A ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bevacizumab; Glioblastoma; Intra arterial chemotherapy; Overall survival; Progression free survival

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; RECURRENT CANCER; REVIEW; SEIZURE; SINGLE DRUG DOSE; WOUND DEHISCENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SEIZURES; SURGICAL WOUND DEHISCENCE; TREATMENT OUTCOME;

EID: 84858039269     PISSN: 18788750     EISSN: 18788769     Source Type: Journal    
DOI: 10.1016/j.wneu.2011.05.056     Document Type: Review

References (20)

1. L.E. Abrey Bevacizumab in recurrent malignant glioma Curr Neurol Neurosci Rep 8 2008 233 234
2. J.A. Boockvar, A.J. Tsiouris, C.P. Hofstetter, I. Kovanlikaya, S. Fralin, K. Kesavabhotla, S.M. Seedial, S.C. Pannullo, T.H. Schwartz, P. Stieg, R.D. Zimmerman, J. Knopman, R.J. Scheff, P. Christos, S. Vallabhajosula, H.A. Riina Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma J Neurosurg 114 2011 624 632
3. C. Calabrese, H. Poppleton, M. Kocak, T.L. Hogg, C. Fuller, B. Hamner, E.Y. Oh, M.W. Gaber, D. Finklestein, M. Allen, A. Frank, I.T. Bayazitov, S.S. Zakharenko, A. Gajjar, A. Davidoff, R.J. Gilbertson A perivascular niche for brain tumor stem cells Cancer Cell 11 2007 69 82 (Pubitemid 46054518)
4. K.A. Carson, S.A. Grossman, J.D. Fisher, E.G. Shaw Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials J Clin Oncol 25 2007 2601 2606 (Pubitemid 47041234)
5. N. Charles, E.C. Holland The perivascular niche microenvironment in brain tumor progression Cell Cycle 9 2010 3012 3021
6. M.H. Cohen, Y.L. Shen, P. Keegan, R. Pazdur FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme Oncologist 14 2009 1131 1138
7. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
8. F.M. Iwamoto, H.A. Fine Bevacizumab for malignant gliomas Arch Neurol 67 2010 285 288
9. T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. Mackey, J.A. Butman, K. Camphausen, J. Park, P.S. Albert, H.A. Fine Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
10. K.R. Lamborn, W.K. Yung, S.M. Chang, P.Y. Wen, T.F. Cloughesy, L.M. DeAngelis, H.I. Robins, F.S. Lieberman, H.A. Fine, K.L. Fink, L. Junck, L. Abrey, M.R. Gilbert, M. Mehta, J.G. Kuhn, K.D. Aldape, J. Hibberts, P.M. Peterson, M.D. Prados Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro Oncol 10 2008 162 170
11. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr. , J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280 (Pubitemid 20195640)
12. H.A. Riina, J.F. Fraser, S. Fralin, J. Knopman, R.J. Scheff, J.A. Boockvar Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma J Exp Ther Oncol 8 2009 145 150
13. H.A. Riina, J. Knopman, J.P. Greenfield, S. Fralin, Y.P. Gobin, A.J. Tsiouris, M.M. Souweidane, J.A. Boockvar Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma A technical note Interv Neuroradiol 16 2010 71 76
14. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, R.O. Mirimanoff Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
15. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J.M. Dowell, D.A. Reardon, J.A. Quinn, J.N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, D.D. Bigner, A.H. Friedman, H.S. Friedman Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 2007 1253 1259 (Pubitemid 46424067)
16. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J. Marcello, D.A. Reardon, J.A. Quinn, J.N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, M. Wagner, L. Bailey, D.D. Bigner, A.H. Friedman, H.S. Friedman Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729 (Pubitemid 350086473)
17. R. Wang, K. Chadalavada, J. Wilshire, U. Kowalik, K.E. Hovinga, A. Geber, B. Fligelman, M. Leversha, C. Brennan, V. Tabar Glioblastoma stem-like cells give rise to tumour endothelium Nature 468 2010 829 833
18. P.Y. Wen, S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
19. P.Y. Wen, D.R. Macdonald, D.A. Reardon, T.F. Cloughesy, A.G. Sorensen, E. Galanis, J. Degroot, W. Wick, M.R. Gilbert, A.B. Lassman, C. Tsien, T. Mikkelsen, E.T. Wong, M.C. Chamberlain, R. Stupp, K.R. Lamborn, M.A. Vogelbaum, M.J. van den Bent, S.M. Chang Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
20. E.T. Wong, K.R. Hess, M.J. Gleason, K.A. Jaeckle, A.P. Kyritsis, M.D. Prados, V.A. Levin, W.K. Yung Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 1999 2572 2578 (Pubitemid 29368260)